Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab was shown to be safe and effective for the treatment of Crohn’s disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [P...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermeire, Séverine, Lukáš, Milan, Magro, Fernando, Adsul, Shashi, Lindner, Dirk, Rosario, Maria, Roth, Jeannine, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476636/
https://www.ncbi.nlm.nih.gov/pubmed/32060515
http://dx.doi.org/10.1093/ecco-jcc/jjaa027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476636/
https://www.ncbi.nlm.nih.gov/pubmed/32060515
http://dx.doi.org/10.1093/ecco-jcc/jjaa027

Ejemplares similares